A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate

Bibliographic Details
Main Authors:	Elizabeth Docteur, Joshua Cohen, Brian K Bruen, Ruth Lopert, Avi Dor, Chuck Shih
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2015-12-01
Series:	Journal of Pharmaceutical Policy and Practice
Subjects:	Analytical Framework Radical Innovation Sales Price Therapeutic Advantage Reimbursement Policy
Online Access:	https://www.tandfonline.com/doi/10.1186/2052-3211-8-S1-P26

Similar Items

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
by: Elizabeth Docteur, et al.
Published: (2015-12-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
by: Michael Kossmeier, et al.
Published: (2021-08-01)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
by: Hajer Dahmani, et al.
Published: (2023-12-01)

The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020
by: Paola Raimondo, et al.
Published: (2020-12-01)

The timelines for the price and reimbursement authorization in Italy 2018–2020
by: Valentina Gallo, et al.
Published: (2022-12-01)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01)

Reimbursement measures in European countries – findings of a bibliometric literature review
by: Sabine Vogler, et al.
Published: (2015-12-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
by: Xavier Badia, et al.
Published: (2020-08-01)

The impact of Ghana’s National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
by: Dumebi O Mordi, et al.
Published: (2015-12-01)

Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness
by: Claudio Jommi, et al.
Published: (2022-09-01)

Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement
by: Dong-Sook Kim, et al.
Published: (2021-08-01)

Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)

Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies
by: Vivian Chen, et al.
Published: (2023-12-01)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023-10-01)

Equivalent Modes of Reimbursement in Augmented Contests
by: Chen Cohen, et al.
Published: (2023-03-01)

Health technology assessment and reimbursement of pharmaceuticals in Italy
by: F. V. Gorkavenko, et al.
Published: (2019-07-01)

Outcome-based reimbursement in Central-Eastern Europe and Middle-East
by: Ildikó Ádám, et al.
Published: (2022-09-01)

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges
by: Andrea Mantovani, et al.
Published: (2023-02-01)

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
by: José Luis Poveda, et al.
Published: (2023-01-01)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
by: David Elvira, et al.
Published: (2023-10-01)

Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
by: Kyung-Bok Son
Published: (2020-10-01)

New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01)

Financial incentives for generic drugs: case study on a reimbursement program
by: Marcos Inocencio, et al.
Published: (2010-06-01)

Financial incentives for generic drugs: case study on a reimbursement program
by: Marcos Inocencio, et al.
Published: (2010-06-01)

The Impact of the Clinical Miscoding on Inpatient Reimbursement
by: Roghayeh Ershad Sarabi, et al.
Published: (2020-03-01)

Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
by: SungKyung Lee, et al.
Published: (2023-02-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement
by: Joshua P. Cohen, et al.
Published: (2014-04-01)

Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview
by: Naina R. Verghese, et al.
Published: (2019-01-01)

Will a Fixed Price Reimbursement Policy for Statins be Cost-Effective for Turkey's Health Care System?
by: Guvenc Kockaya, et al.
Published: (2010-01-01)

Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach
by: F. Antoñanzas, et al.
Published: (2019-10-01)

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions
by: Stavros Simeonidis, et al.
Published: (2019-08-01)

A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
by: Patricia Vella Bonanno, et al.
Published: (2021-11-01)

Reimbursement for Emergency Department Electrocardiography and Radiograph Interpretations: What Is It Worth for the Emergency Physician
by: Wu, Tina, et al.
Published: (2009-08-01)